Selvita S.A., a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.
Santhera licenses CF drug from Polyphor
Latest NewsSanthera Pharmaceuticals has licenced the inhaled neutrophil eleastase blocker POL6014 from Polyphor Ltd for CHF6.5m upfront and CHF121m in potential milestones.
AML: Sorafenib boosts graft-versus-leukemia activity
Latest NewsCo-administration of an allogenic blood stem cell transplant and sorafenib cured AML patients refractive to chemotherapy and stem cell transplants alone, oncologists report in Nature Medicine.
Poxel in €506m diabetes deal with Roivant Sciences
Latest NewsPoxel S.A. is advancing its proof-of-concept type 2 diabetes programme imeglimin (PXL008) into Phase III studies in the US an the EU by means of a licence deal with Swiss Roivant Sciences GmbH.
Pieris inks US$1.2bn immuno-oncology deal with Seattle Genetics
Latest NewsAnticalin developer Pieris and Antibody-drug conjugate specialist Seattle Genetics have agreed to co-develop three bispecific cancer drugs using Seattle Genetic’s cancer targets and Pieris’ co-stimulatory agonist and anticalin platform.
Spanish biotech sector attracts investors
BackgroundSpanish biotech sector:?European investors more and more often take a look at Southern European biotech companies. Spain, in particular, is now harvesting the fruits of long-term public support started a decade ago, which stimulated the establishment of a dynamic ecosystem. Today, foreign investments are at an all-time high and start-ups find a well-prepared basis for growth.
DMD drug aids heart failure patients
Latest NewsItalfarmaco SpA’s Givinostat, a small molecule histone deacetylase (HDAC) inhibitor in clinical testing against several forms muscular dystrophies, is also an option to treat heart failure with preserved ejection fraction (HFpEF), a form of congestive heart failure that affects 50% of heart failure patients.
New target could minimise transplant risks
Latest NewsGerman researchers have identified a target to switch off intestinal acute graft-versus-host disease (GVHD), which occurs in about 50% of leukemia patients that have been given a allogeneic hematopoietic cell transplantation (allo-HCT).
Addex Appoints Jean-Philippe Rocher as Co-Head Discovery
AppointmentsAddex Therapeutics, a leading company in allosteric modulation-based drug discovery and development, announced today the appointment of Jean-Philippe Rocher, PhD, as Co-Head of Discovery and Member of the Executive Management, effective 1 June 2018.
EU General Court rejects industry’s confidentiality claims
Latest NewsThe European Medicines Agency (EMA) has won a landmark battle about the amount of data from clinical dossiers that may be made public. The European Court of Justics (EJC) rejected the demand of three drug developers not to publish what they called confidential information under the EMA’s transparency rules.
Selvita appoints new Chief Medical Officer
AppointmentsSelvita S.A., a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.